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costs were used. Price for sofosbuvir-ledipasvir was the price used in the early access 
program in France. Results: The incremental cost-effectiveness ratio for patient 
treated at F2F3 ranged from 3 000 € / QALY to 20 000 € / QALY for 8 and 12 weeks treat-
ment duration. The sensitivity analyses carried out confirmed the robustness of this 
result. ConClusions: Sofosbuvir-ledipasvir association is a cost-effective treatment 
option for patients with hepatitis C in most clinical contexts.
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objeCtives: The prevalence of carbapenem-resistant Enterobacteriaceae(CRE) has 
been increasing and proactive surveillance is highly recommended. Patients in inten-
sive care unit (ICU) are particularly prone to CRE acquisition due to multiple risk 
factors. The objective of this study was to examine the potential cost and clinical 
outcomes of active CRE surveillance upon ICU admission from the perspective of 
healthcare providers in Hong Kong. Methods: A Markov model was designed to 
compare the outcomes of active CRE surveillance versus no active surveillance in 
patients admitted to an ICU in Hong Kong. CRE-associated direct medical cost and 
CRE-associated quality-adjusted life years (QALYs) loss were simulated based on the 
model inputs derived from the literature. Sensitivity analyses were conducted to 
evaluate the robustness of the results. Results: In the base-case analysis, active sur-
veillance group showed less QALYs loss (0.3335 vs 0.3827) with higher CRE-associated 
cost (HKD9,825 vs HKD9,800) (USD1= HKD7.8) than control group. The incremental 
cost-effectiveness ratio (ICER) of active surveillance was HKD 500 per QALY saved 
compared to control group. Sensitivity analysis found base-case results robust to 
variation of all model inputs. In 10,000 Monte Carlo simulations, active surveillance 
group was less costly by HKD1,064 per patient (95%CI HKD1,025-1,103; p< 0.001) and 
lower mean QALYs loss by 0.430 (95% CI, 0.422-0.438; p < 0.001) when compared with 
control group. ICERs per QALY saved by the active surveillance group were less than 
the gross domestic product per capita in Hong Kong (HKD330,113) in 99.98% of the 
simulations. ConClusions: Active CRE surveillance upon ICU admission appears to 
be a cost-effective strategy from the perspective of healthcare providers in Hong Kong.
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objeCtives: Sofosbuvir (SOF), a new pan-genotypic inhibitor of the hepatitis C 
virus (HCV), has been approved for use in chronic hepatitis C (CHC) patients, 
having shown unprecedented sustained virologic response (SVR) rates and tol-
erability profile. More recently, the combination of SOF and ledipasvir (LDV) – a 
new HCV inhibitor with potent antiviral activity – has resulted in higher rates of 
SVR, especially in genotype-1 HCV. The objective of this analysis was to assess 
the cost-effectiveness of LDV/SOF fixed-dose combination for the treatment of 
HCV genotype-1 in Portugal. Methods: Cost and effectiveness were based on a 
CHC natural history evolution Markov-type model accounting for the presence 
of cirrhosis and previous treatment experience for genotype-1. The model incor-
porated 5 Metavir score states, 2 SVR states (with and without cirrhosis) and 3 
advanced liver disease states. Results are expressed in incremental costs per life 
year (LY) and quality-adjusted life year (QALY). The choice of comparators was 
based on identical therapeutic indication and financing by the Portuguese National 
Healthcare System (except for SOF which is currently seen as the standard of 
care). Results: Overall LDV/SOF is expected to result in increments between 0.21 
and 6.80 LY (0.26 and 5.80 QALY) depending on the clinical subgroup and compara-
tor, with costs ranging from -56,981€ savings and 23,288€ increment. Incremental 
cost-effectiveness ratios (ICER) varied between LDV/SOF dominance and a maxi-
mum of 10,563€ /LY (9,098€ /QALY). In the comparison against SOF+PegIFN+RBV or 
SOF+RBV, LDV/SOF was shown to be dominant, while versus boceprevir regimens 
ICER varied between 1,896€ /LY (2,597€ /QALY) (experimented cirrhotic) and 10,563€ /
LY (9,098€ /QALY) (experimented non-cirrhotic). When LDV/SOF was compared 
against PegIFN+RBV, the ICER variation was 3,828€ /LY (5,396€ /QALY) (naïve cir-
rhotic) to 8,042€ /LY (6,776€ /QALY) (experimented non-cirrhotic). ConClusions: 
Ledipasvir/sofosbuvir is expected to represent good value for money including 
cost-saving scenarios in the treatment of CHC genotype-1 in Portugal, irrespective 
of the clinical subgroup or comparator.
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objeCtives: Rectal culture-guided antibiotic prophylaxis is an effective strategy 
in preventing post-TRUSBx infections. This study aimed to examine the cost-effec-
tiveness of pre-biopsy rectal swab culture-guided antibiotic prophylaxis in patients 
undergoing TRUSBx from the societal perspective in Hong Kong. Methods: A deci-
sion tree model was designed to compare clinical outcomes and cost of TRUSBx with 
rectal culture-guided versus empirical antibiotic prophylaxis in a hypothetical cohort 
caspofungin. The cost of achieving one more patient successfully treated with anid-
ulafungin, caspofungin, and micafungin compared to fluconazole was € 17,199, € 
23,962, and € 27,339, respectively. The result remained stable despite modification 
of the duration of the first-line and second-line treatments, as well as most of the 
dosing regimens. The probabilistic analysis also remained stable. ConClusions: 
According to the model, anidulafungin produced savings and was the dominant 
treatment compared with micafungin and caspofungin in non-neutropenic adult 
patients with candidemia and/or invasive candidiasis in ICUs in Spain.
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objeCtives: Rotavirus (RV) infection is a leading cause of severe diarrhoea among 
young children in Switzerland and it is associated with a significant financial 
burden. Two RV vaccines are marketed globally, but only RIX4414 is licensed in 
Switzerland. This study aims to evaluate the cost-effectiveness of RV vaccination 
with RIX4414 among children less than 5 years of age in Switzerland. Methods: A 
previously published age-compartmental Markov cohort model with monthly cycles 
was used to evaluate the RV events and the associated health outcomes and costs 
over the first 5 years of a new-born cohort. It compared the RV burden in a cohort of 
84,823 new-borns with or without RIX4414. Transition probabilities, vaccine efficacy, 
Quality-Adjusted-Life-Years (QALY), Swiss specific incidence and costs data were 
obtained from literature or official reports. Retail vaccine price of CHF61.60 per 
dose was used. Incremental cost-effectiveness ratio (ICER) was calculated under 
a payer’s perspective. Extensive sensitivity analyses were also performed to test 
the robustness of the results. Results: The vaccination programme with RIX4414 
at 90% coverage rate would prevent 1,411 hospitalisation (88%), 145 nosocomial 
infections (63%), 3,914 emergency room visits (88%), 13,006 medical visits (87%) and 
27,861 (70%) RV events. From a payer’s perspective, the vaccine cost completely offset 
the direct RV medical cost and vaccination may offer 39 extra QALYs. Sensitivity 
analyses showed that the frequency of medical visits, of RV events and the cost of 
hospitalisation were the key drivers influencing the results. ConClusions: RV 
vaccination programme with RIX4414 could reduce substantially the number of RV 
cases. The vaccine cost offsets the total direct medical costs.
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objeCtives: In the European context, the nonavalent HPV vaccine 
(6/11/16/18/31/33/45/52/58) expands the spectrum of prevention from 75% to 89% 
of HPV-positive cancer cases and from 47% to 82% of precancerous lesions in the cer-
vix, vulva, vagina and anus. This analysis aims to estimate the public health impact 
and the incremental cost-effectiveness of a universal (girls and boys) vaccination 
program with a nonavalent HPV vaccine as compared to the current universal vacci-
nation program with a quadrivalent HPV vaccine (6/11/16/18), in Austria. Methods: 
A dynamic transmission model including a wide range of health and cost out-
comes related to cervical, anal, vulvar, vaginal diseases and genital warts was 
calibrated to Austrian epidemiological data. The clinical impact due to the 5 new 
types was included for cervical diseases only, producing conservative outcomes. In 
the base case, a two-dose schedule, lifelong vaccine type-specific protection and 
a vaccination coverage rate of 60% and 40% for girls and boys respectively for the 
9-year old cohorts were assumed. A threshold of € 30,000/QALY-gained was consid-
ered. Results: Universal vaccination with the nonavalent vaccine was shown to 
be having the potential to reduce the incidence of HPV16/18/31/33/45/52/58 -related 
cervical cancer by 92% and the related CIN2/3 by 96% after 100 years, relative to 75% 
and 76% with the quadrivalent vaccine respectively. Furthermore, the nonavalent 
vaccine was projected to prevent an additional of 8,281 cases of CIN1, 14,893 cases 
of CIN2/3 and 2,544 cases of cervical cancer, over 100 years. Finally, the base case 
analysis resulted into an ICER of approximately € 16,441. ConClusions: The find-
ings of the analysis indicate that universal vaccination with a nonavalent vaccine 
in Austria is estimated to be cost-effective when compared to the quadrivalent 
vaccine across a range of sensitivity analyses and, further reduce the public health 
burden of HPV-related cancers and diseases.
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objeCtives: In France, 190,306 patients were suffering from chronic hepatitis C in 
2012. These patients have a decreased life expectancy and are susceptible to complica-
tions associated with chronic hepatitis. The association of Ledipasvir and Sofosbuvir, 
an interferon-free treatment, has demonstrated in several phase III trials sustained 
viral response (SVR) rates close to a 100% for genotype 1 (G1) and 4 (G4) patients in 
8 to 12 weeks. The objective of this study was to compare the cost-effectiveness of 
using this association in the treatment of chronic HCV infection in multiple clinical 
context including past treatment (naïve or experience), coinfection, cirrhosis and 
stage at treatment initiation. Methods: A Markov model was used to assess the cost-
effectiveness of sofosbuvir-ledipasvir association compare to every available current 
and upcoming strategy. The model simulated the natural history of HCV infection 
from F0 to F4 taking into account the characteristics of the patients at treatment. To 
be conservative, the model also included fibrosis progression for SVR patients. SVR 
rates for F0 to F4 were based on data from clinical trials. Utilities associated with dif-
ferent stages of disease were based on data from the literature. French direct medical 
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bACkgRound: Invasive Aspergillosis(IA) is a serious invasive fungal 
infection(IFI), usually affecting immunocomprised patients. In the Netherlands, 
voriconazole(VOR) is the recommended primary targeted antifungal agent and is 
used for the vast majority of IA patients. After unsuccessful first line treatment 
with VOR, Caspofungin(CASP) and liposomal amphotericin B(L-AMB) are two most 
commonly used agents. In a previously published study, CASP was dominant over 
L-AMB, as a targeted salvage antifungal therapy option after VOR for IA treatment 
in the Netherlands. However, trial data used as input might not reflect the real 
world effectiveness of treatment strategies. objeCtives: The objective of this 
study is to conduct a cost-effectiveness analysis of the most common targeted 
antifungal treatment sequences for IA in the Netherlands, using real-world data 
from a national registry. Methods: A previously developed decision analytical 
model was adapted to carry out the cost-effectiveness analysis that compares 
L-AMB vs. CASP as a 2nd line treatment strategy after unsuccessful treatment 
with VOR. Findings from the analysis of the national patient registry informed the 
model structure, treatment patterns, duration/dosage of treatments, events and 
their probabilities. The model estimates both survival during infectious disease 
episode as well as life years saved(LYS) after short-term survival. Extensive sensi-
tivity analyses were conducted to assess the robustness of the results. Results: 
Short term survival, life expectancy and cost outcomes for using L-AMB and CASP 
in the 2ndline seem to be similar, after an unsuccessful primary therapy with 
VOR. There is a slight benefit in terms of LYS and costs for L-AMB. The analysis 
results are sensitive to statistical uncertainty due to the low number of patients 
in the registry. ConClusions: An updated analysis after more data is collected 
would strengthen reliability/validity of the analysis, and would make it feasible 
to apply statistical matching Methods to adjust for possible confounding by treat-
ment choice.
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objeCtives: Rapid advances in the development of direct-acting antivirals (DAAs) 
have shifted the challenge of treating chronic hepatitis C virus (HCV) from a medical 
challenge to a socioeconomic issue of affordability. A 12-week course of all-oral DAA 
costs approximately USD 84,000. To date, no study has been conducted to determine 
the cost-effectiveness of various DAAs within an Asian context. Methods: We per-
formed a Markov model to simulate a cohort of 50 year-old HCV infected patients 
through 14 treatment strategies over life-time period. Treatment effects including 
sustained virological response and adverse events including anemia, neutropenia and 
thrombocytopenia were derived from published trials. Costs were obtained from a ter-
tiary hospital in Singapore. Subset analysis was conducted to incorporate the implica-
tion of retreatment that reflected real-life situation. Results: Using response-guided 
boceprevir (BOC/RGT, least costly treatment) as a base-case, peginterferon/ribavirin, 
48-week boceprevir and genotype-guided therapies were dominated by BOC/RGT as 
they were more costly and less effective. Using the Singapore gross domestic product 
of USD 52,500 as the threshold, 12 weeks of Viekira Pak (ombitasvir/paritaprevir/rito-
navir/dasabuvir) and sofosbuvir/ledipasvir were cost-effective and marginally cost-
effective respectively. Other all-oral DAAs were either dominated by Viekira Pak or 
sofosbuvir/ledipasvir. Roadmap therapy using rapid virologic-response to guide use of 
boceprevir and sofosbuvir was associated with favourable incremental cost per qual-
ity-adjusted life year gained (USD 16,130). BOC/RGT and roadmap therapy remained 
as cost-effective treatment options by incorporating retreatment. ConClusions: 
HCV management can be optimised by adopting value-based treatment algorithm 
such as roadmap therapy that offers best value for money.
PIN62
Cost-EffECtIvENEss of CoNjugAtE PNEumoCoCCAl vACCINAtIoN IN 
CroAtIA
Bencina G1, Van de Velde N2
1GSK, Zagreb, Croatia, 2GSK Vaccines, Wavre, Belgium
objeCtives: Streptococcus pneumonia causes a number of clinical conditions, 
including pneumonia, meningitis, bacteremia, sepsis, and acute otitis media (AOM). 
The objective of this study is to estimate the potential effectiveness and cost-effec-
tiveness of vaccinating infants with the pneumococcal non-typeable Haemophilus 
influenzae Protein D conjugate vaccine (PHiD-CV) compared to the 13-valent pneu-
mococcal conjugate vaccine (PCV-13) in Croatia. These vaccines are currently avail-
able only for risk groups and on private market with a limited uptake, representing 
less than 10% of annual birth cohort. Methods: A Markov cohort model with a 
starting birth cohort of 39,939 infants and a 100-year time horizon was used to 
project the impact of vaccination on the incidence of pneumococcal diseases. In 
the model, individuals move between mutually-exclusive health states and direct 
treatment costs and quality-adjusted life years (QALYs) are aggregated and dis-
counted (3%) in monthly cycles. Vaccine regimen was 2+1 schedule with doses given 
at 2, 4, and 13 months for both vaccines. Results: Under our model assumptions 
and assuming both vaccines have the same price, PHiD-CV is predicted to save 
both 13 QALYs and € 138,564 compared to PCV-13 (dominant intervention). Both 
vaccines would prevent about the same numbers of IPD and pneumonia whereas 
PHiD-CV would save more GP visits and clinical interventions related to AOM. If the 
model further accounts for the difference in list price between the two vaccines, 
then vaccinating Croatian infants with PHiD-CV would save a total of € 1,192,753 
compared to PCV-13. Parameters infuencing the most model results are related to 
AOM management (e.g. percentage reduction in myringotomy and disutility for 
outpatient AOM). ConClusions: Our results show PHiD-CV dominates PCV-13 in 
most scenarios due to incremental benefits in AOM. Vaccinating with PHiD-CV in 
Croatia could save a substantial health care budget.
of male patients. Total costs (direct medical cost, indirect cost) and quality-adjusted 
life-year (QALY) loss for post-biopsy infection care were outcomes of analysis. Model 
inputs were retrieved from clinical studies published in literature. Sensitivity analysis 
was conducted to examine robustness of model results. Results: The base-case 
analysis found rectal culture-guided strategy to be less costly (expected cost HKD1,268 
versus HKD1,633) (USD1= HKD7.8) with lower QALY loss (0.00055 QALY vs 0.00084 
QALY) when compared to empirical strategy. Sensitivity analysis showed that the 
total cost of rectal culture-guided arm would become higher than the empirical arm 
if the effectiveness of rectal culture-guided strategy in reducing post-biopsy infec-
tion was less than 12.07%, or if post-biopsy infection rate of empirical strategy was 
lower than 3.18%. In 10,000 Monte Carlo simulations, rectal culture-guided arm was 
the preferred option in 98.67% of cases with mean total cost saving of HKD449 per 
patient (95%CI HKD443–455; p < 0.001) and lower mean QALY loss of 0.000335 QALYs 
per patient (95%CI 0.000332–0.000338 QALYs; p < 0.001). ConClusions: Comparing 
with empirical antibiotic prophylaxis, the use of rectal swab culture to guide the 
choice of antibiotic prophylaxis seems to be a cost-saving and effective intervention 
in men undergoing TRUSBx in Hong Kong.
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objeCtives: Chronic hepatitis C virus (HCV) is a considerable public health concern 
due to its significant impact on morbidity, mortality and healthcare costs. Treatment 
of HCV genotype 1 (GT1)-infected patients with ombitasvir/paritaprevir/ritonavir and 
dasabuvir with or without ribavirin (OBV/PTV/r/DSV±R) demonstrated significantly 
high sustained viral response (SVR) rates and negligible adverse events in clinical 
studies. This study evaluated the cost per SVR for OBV/PTV/r/DSV±R compared to 
sofosbuvir in combination with daclatasvir (SOF+DCV) or simeprevir (SOF+SIM) in 
HCV treatment-naïve patients with GT1 for The Netherlands. Methods: An eco-
nomic evaluation comparing OBV/PTV/r/DSV±R to SOF+DCV or SOF+SIM in terms of 
costs per SVR was performed from the Dutch societal perspective. A Markov model 
with a lifetime time horizon was developed based on previous published models in 
HCV. Transition probabilities, resource use and costs for reference year 2014 were 
derived from the literature, publically available sources and expert opinion. SVR rates 
for all therapies were derived from published literature. Baseline characteristics (e.g., 
age, fibrosis distribution) were based on the OBV/PTV/r/DSV±R trials. Results: In 
treatment-naïve HCV GT1 patients, the overall trial SVR rate for OBV/PTV/r/DSV±R 
was 97% (688/708), 98% (124/126) for SOF+DCV and 89% (17/19) for SOF+SIM. Total 
costs were lower for OBV/PTV/r/DSV±R (€ 55,864) compared to SOF+DCV (€ 83,679) 
and SOF+SIM (€ 81,746). Total costs per SVR were also lower for OBV/PTV/r/DSV±R 
(€ 57,592) compared to SOF+DCV (€ 85,387) and SOF+SIM (€ 91,849). Treatment with 
OBV/PTV/r/DSV±R resulted in a cost-savings of € 27,795 and € 34,257 per responding 
patient compared to SOF+DCV and SOF+SIM, respectively. ConClusions: Total costs 
per successfully treated treatment-naïve HCV GT1 patient with OBV/PTV/r/DSV±R 
are lower compared to sofosbuvir in combination daclatasvir or simeprevir for the 
Dutch society. Treatment with OBV/PTV/r/DSV±R would lead to cost-savings and thus 
improve the overall budget impact of HCV in the Netherlands.
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objeCtives: To assess cost-effectiveness of voriconazole compared to other medi-
cations recommended in Russia for treatment of invasive aspergillosis (IA) in 
adults. Methods: We developed «decision tree» model, comparing 3 alternative 
first-line therapies in IA: 1) voriconazole, 2), caspofungin, or 3) amphotericin B lipid 
complex (LC). Efficacy was assessed as the probability of patient survival within 14 
weeks of starting treatment. Transition probabilities were calculated on the basis 
of data derived from published clinical research on IA treatment. Costs were cal-
culated as the sum of drugs cost (based on prices in public procurement) and cost 
of prolonged stay in hospital due to serious adverse events (based on the average 
bed-day cost in public health care). In additional model, conventional ampho-
tericin B instead of its LC was administered. Probabilistic sensitivity analysis was 
performed for both models. Costs were converted to EUROs using the average 
weighted exchange rate in 2014 (1€ = 50.815RUR). Results: In the base case model 
voriconazole was a dominant strategy for IA treatment (per patient survival 0.742 
and cost € 10,556) in comparison with caspofungin (0.652 and € 17,272, respectively) 
and amphotericin B lipid complex (0.719 and € 34,441). Probabilistic sensitivity 
analysis (1000 simulations) showed the robustness of results. In additional model 
the willingness-to-pay threshold, at which voriconazole had more chances to 
be considered cost-effective in comparison with conventional amphotericine B 
varied from € 984 to € 21,647 per life saved, depending on the choice of second 
line therapy. ConClusions: Voriconazole was shown to be either dominant or 
cost-effective strategy for treatment of IA in comparison with other therapies 
recommended in Russian practice.
PIN60
ECoNomIC EvAluAtIoN of tArgEtEd ANtIfuNgAl trEAtmENt 
sEquENCINg strAtEgIEs for INvAsIvE AsPErgIllosIs bAsEd oN rEAl 
world dAtA: tHE CAsE of dutCH ClINICAl PrACtICE
Buyukkaramikli N1, van Agthoven M2, Leunis A1, Severens JL1
1Erasmus University, Rotterdam, The Netherlands, 2GILEAD Sciences, Amsterdam, The 
Netherlands
